Merck Sharp & Dohme (Australia) Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
340 result(s) found, displaying 41 to 50
-
Apr-2024Prescription medicine evaluationActive ingredient: belzutifan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XELEVIA sitagliptin (as phosphate monohydrate) 25 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JANUVIA sitagliptin 50mg (as phosphate monohydrate) tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JANUVIA sitagliptin 100mg (as phosphate monohydrate) tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XELEVIA sitagliptin (as phosphate monohydrate) 50 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JANUVIA sitagliptin 25mg (as phosphate monohydrate) tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for XELEVIA sitagliptin (as phosphate monohydrate) 100 mg film-coated tablet blister pack.
-
Prescription medicine registrationActive ingredients: pembrolizumab.
-
Prescription medicine registrationActive ingredients: tucatinib.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd